Who are RIFINAH ©'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): isoniazid and rifapentine, Tuberculosis treatment, isoniazid , randomized, open label, RNTCP Category I treatment for 6 months, Rifampin-free regimen, RNTCP Category I treatment for 9months.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rifinah.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

RIFINAH © — Competitive Intelligence Brief

RIFINAH © (RIFINAH ©) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitubercular. Area: Infectious Diseases.

phase 3 Antitubercular RNA polymerase beta-subunit Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

RIFINAH © (RIFINAH ©) — Assistance Publique - Hôpitaux de Paris. Rifinah is an antitubercular medication that works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RIFINAH © TARGET	RIFINAH ©	Assistance Publique - Hôpitaux de Paris	phase 3	Antitubercular	RNA polymerase beta-subunit
isoniazid and rifapentine	isoniazid and rifapentine	National Taiwan University Hospital	phase 3	Antitubercular agent	InhA (enoyl-acyl carrier protein reductase), RNA polymerase
Tuberculosis treatment	Tuberculosis treatment	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Antitubercular	InhA
isoniazid , randomized, open label	isoniazid , randomized, open label	National Taiwan University Hospital	phase 3	Antitubercular agent	InhA
RNTCP Category I treatment for 6 months	RNTCP Category I treatment for 6 months	All India Institute of Medical Sciences	phase 3	Antitubercular	InhA (Isoniazid target)
Rifampin-free regimen	Rifampin-free regimen	Nantes University Hospital	phase 3	Antitubercular
RNTCP Category I treatment for 9months	RNTCP Category I treatment for 9months	All India Institute of Medical Sciences	phase 3	Antitubercular	InhA (Isoniazid target)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitubercular class)

All India Institute of Medical Sciences · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
LigaChem Biosciences, Inc. · 1 drug in this class
Nantes University Hospital · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
The Aurum Institute NPC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RIFINAH © — Competitive Intelligence Brief. https://druglandscape.com/ci/rifinah. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab